A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

430

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

August 31, 2031

Study Completion Date

August 31, 2031

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Telisotuzumab Adizutecan

Intravenous (IV) Infusion

DRUG

Standard of Care